BREAKING: GOODRX HAS SAVED AMERICANS AN ESTIMATED $70 BILLION ON PRESCRIPTIONS ~30 MILLION UNIQUE USERS FY2025 REVENUE $796.9M NASDAQ: GDRX GOODRX COMPANION LAUNCHED MAY 2026 - $14.99/MO FOUNDED 2011 IN SANTA MONICA, CA BREAKING: GOODRX HAS SAVED AMERICANS AN ESTIMATED $70 BILLION ON PRESCRIPTIONS ~30 MILLION UNIQUE USERS FY2025 REVENUE $796.9M NASDAQ: GDRX GOODRX COMPANION LAUNCHED MAY 2026 - $14.99/MO FOUNDED 2011 IN SANTA MONICA, CA
YesPress Profile · Healthtech
GoodRx logo

GoodRx

The company that walked into an American pharmacy, asked the rude question - "how much, really?" - and built a business on the answer.

Above: the GoodRx wordmark. Yes, the "Rx" is doing a lot of work. So is the company.

Est. 2011 Santa Monica, CA Nasdaq: GDRX ~700+ employees

A patient stands at a pharmacy counter, phone in hand. The pharmacist names a number. The patient names a smaller one, reading it off a coupon. The smaller number wins. This small, slightly awkward standoff happens millions of times a day - and it is, in essence, the entire GoodRx product.

GoodRx is a digital healthcare platform built on a deceptively simple premise: that you should be allowed to know what your medicine costs before you pay for it. Roughly 30 million Americans have used it. It aggregates real-time prices and discounts from pharmacies across the country, hands consumers free coupons, and - increasingly - wraps telehealth visits, manufacturer savings, and employer programs around that core search box.

Fifteen years in, it is profitable, public, and still arguing the same point it opened with.

"Type in a pill. Get a price. The radical part is that this was ever radical."

- The GoodRx pitch, distilled
The Problem They Saw

A prescription is not a price tag

Here is the inconvenient truth GoodRx was built around: in the United States, the same drug can cost wildly different amounts depending on which pharmacy you walk into, what your insurance is, and whether anyone bothered to tell you. Cash prices swing. Coupons sometimes beat insurance copays. The numbers are real, but nobody publishes them in one place.

The story the founders tell is almost too tidy. In 2010, co-founder Doug Hirsch went to fill a prescription, balked at the price, and started shopping around - only to find there was no single place to compare. Two pharmacies on the same street, two very different numbers, and no map. That gap between what a drug costs and what you're told it costs is the tension the whole company runs on.

"The prices were always there. They were just never in the same room as the patient."

- On why drug-price transparency needed inventing
The Founders' Bet

Three people who knew how to build a search box

GoodRx was founded in 2011 in Santa Monica by Doug Hirsch, Scott Marlette, and Trevor Bezdek. Two of them - Hirsch and Marlette - came out of Facebook's early product ranks; Hirsch had also been among Yahoo!'s first thirty employees. They were, in other words, people who understood that the answer to "how do I find the cheapest thing" is usually a well-built index, not a phone call.

The bet was unfashionable for healthcare: don't charge the patient. Make the tool free, aggregate the messy pricing data nobody else had organized, and figure out the money later. It turned out "later" meant fees from the pharmacy-benefit middlemen who suddenly had a reason to route discounted volume through GoodRx.

Co-Founder

Doug Hirsch

Ex-Yahoo! (first ~30 employees), ex-Facebook VP of Product. The one who actually got sticker shock at the counter.

Co-Founder

Trevor Bezdek

The technologist of the trio; served as co-CEO as GoodRx scaled from coupon site to public company.

Co-Founder

Scott Marlette

Also out of early Facebook. Helped turn a pile of pricing data into something people could search.

Three founders, two of them Facebook alumni, all of them convinced a pharmacy receipt should not be a surprise party.

The Product

What you can actually do with it

At its heart, GoodRx is free. You search a medication, see prices across nearby pharmacies, and pull up a coupon that frequently lands below the cash price - and sometimes below your own insurance copay. That is the part most people meet first. Around it, the company has built a fuller stack:

The core

Discounts & Coupons

Real-time price comparison across U.S. pharmacies, with free coupons. Always the front door.

Subscription

GoodRx Companion

Launched May 2026 at $14.99/mo: low-cost generics, $19 telehealth visits, plus dental, vision, lab and imaging savings.

Care

GoodRx Care

Online doctor visits and prescribing for common conditions, stitched to the pharmacy savings.

B2B engine

Pharma Direct

Manufacturer affordability programs - including GLP-1s like Wegovy and Zepbound - routed to self-pay patients.

B2B

Employer Direct

Launched Feb 2026: employer-funded subsidies that cut out-of-pocket costs on high-impact brand drugs.

Editorial

GoodRx Health

A consumer library of medication and health information, written by clinicians.

"Free for the patient. Paid for by everyone who suddenly wanted the patient's business."

- The GoodRx business model in one breath

The receipts

A timeline, lightly editorialized
2010
The sticker shock. Doug Hirsch shops a prescription, finds no place to compare prices. Annoyance becomes a company.
2011
GoodRx founded in Santa Monica. First funding: a $1.5M Series A with Lerer Hippeau, Upfront Ventures and SV Angel.
2015
1 million monthly users. The coupon habit goes mainstream.
2018
Big money arrives. Silver Lake, Francisco Partners and Spectrum Equity back the company; reported investment north of $700M.
2020
IPO on Nasdaq (GDRX). Raises ~$1.1B at a ~$12.7B valuation; shares pop to a ~$17.9B market cap.
2026
The bundle era. Employer Direct (Feb) and the $14.99/mo Companion subscription (May) push GoodRx beyond the coupon.
The Proof

The numbers do the arguing

Skeptics are right to ask whether a free coupon site can be a real business. The financials suggest it can. GoodRx posted FY2025 revenue of $796.9M with an adjusted EBITDA margin near 34% - healthy by any software standard, let alone healthcare. Its pharma-manufacturer business has become a genuine growth engine, with Pharma Direct revenue up 41% to $151M and Q1 2026 revenue of $194.0M.

Where the money sits

Select GoodRx figures · USD
FY25 Rev
$797M
FY25 EBITDA
$271M
Q1'26 Rev
$194M
Pharma Direct
$151M
Bars scaled to FY2025 revenue. Adjusted EBITDA margin ≈ 33.9%. Figures approximate, per company reports.
~30M
Unique users
$70B+
Est. consumer savings
$797M
FY2025 revenue
2011
Founded

Estimated savings of $70B+ is the kind of number that sounds made up until you remember how many people fill a prescription every single day.

The partnerships tell the same story from another angle. Pharmacies and PBMs honor GoodRx pricing at the counter. Drugmakers plug brand affordability programs - the GLP-1 weight-loss drugs especially - into Pharma Direct. Employers now buy subsidies through Employer Direct. Each one is a different party deciding that a patient who can find a price is a patient worth reaching.

"$70 billion in savings, one slightly awkward counter conversation at a time."

- The cumulative GoodRx effect
The Mission

Transparency as a product, not a slogan

GoodRx states its mission plainly: help Americans get the healthcare they need at a price they can afford, by bringing transparency to drug pricing. It is the rare mission statement that doubles as the product spec. The company isn't promising to fix the U.S. healthcare system - a sensible thing to avoid promising - but it is insisting that the first step is letting people see the prices.

The competitive set has noticed. SingleCare, RxSaver, Blink Health, Optum Perks, Amazon Pharmacy, and Mark Cuban's Cost Plus Drugs are all circling the same idea from different directions. Transparency, it turns out, is contagious.

Why It Matters Tomorrow

The front door keeps getting wider

The 2026 moves - Companion, Employer Direct, deeper GLP-1 access - point at where GoodRx wants to go: from a tool you reach for at the counter to a standing relationship with your everyday healthcare costs. Whether a $14.99 subscription can sit comfortably next to a free coupon is the open question, and a strategy pivot is never as clean in practice as it looks in a press release.

But the core thesis hasn't moved an inch since 2011. Prices should be visible. People should be able to choose. Everything else is distribution.

Back at that pharmacy counter: the patient reads the smaller number, the pharmacist rings it up, and the standoff resolves the way it now resolves millions of times a day. The medicine costs what GoodRx says it costs. That used to be a surprise. Now it's just Tuesday.

Spread the word